Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE:301263)

SHE:301263 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	485.13	541.96	455.64	806.79	137.63	93.5
Trading Asset Securities	162.51	122.1	251.8	240.65	-	-
Cash & Short-Term Investments	647.64	664.06	707.45	1,047	137.63	93.5
Cash Growth	-4.17%	-6.13%	-32.46%	661.05%	47.19%	16.95%
Accounts Receivable	374.41	337.06	353.04	378.49	315.95	256.4
Other Receivables	37.77	2.92	4.09	4.1	1.91	3.67
Receivables	412.17	339.98	357.14	382.59	317.86	260.07
Inventory	127.16	105.07	86.55	80.52	76.57	99.82
Other Current Assets	36.24	33.08	36.16	22.53	11.01	20.23
Total Current Assets	1,223	1,142	1,187	1,533	543.07	473.63
Property, Plant & Equipment	511.53	521.27	483.74	314.54	260.24	212.23
Long-Term Investments	32.45	32.45	32.45	32.45	-	-
Goodwill	216.66	216.66	200.64	27.33	27.33	27.33
Other Intangible Assets	180.67	159.25	158.19	66.01	44.46	47.39
Long-Term Deferred Tax Assets	59.55	57.09	32.64	34.19	29.31	24.87
Long-Term Deferred Charges	168.34	174.87	119.98	26.25	26.5	15
Other Long-Term Assets	4.39	7.28	14.18	5.74	10.62	33.05
Total Assets	2,397	2,311	2,229	2,040	941.52	833.49
Accounts Payable	148.8	168.37	121.19	56.59	46.92	32.38
Accrued Expenses	9.4	19.53	18.7	27.64	19.68	15.37
Short-Term Debt	223.35	132.14	53.84	20.02	107.57	126.42
Current Portion of Long-Term Debt	24.78	24.09	12.08	-	-	-
Current Portion of Leases	-	1.58	1.23	1.17	0.96	-
Current Income Taxes Payable	29.03	21.78	37.02	41.54	16.55	14.28
Current Unearned Revenue	3.42	3.21	4.19	5.18	9.04	18.88
Other Current Liabilities	4.36	4.26	4.89	4.17	3.76	8.05
Total Current Liabilities	443.14	374.95	253.13	156.33	204.48	215.38
Long-Term Debt	72	84	108	-	-	-
Long-Term Leases	1.35	0.85	1.12	1.96	0.37	-
Long-Term Unearned Revenue	14.72	15.65	16.19	19.66	19.08	19.66
Long-Term Deferred Tax Liabilities	18.71	19.21	21.28	7.68	7.79	8.81
Total Liabilities	549.92	494.67	399.72	185.63	231.71	243.86
Common Stock	425.5	425.5	425.5	236.39	177.29	177.29
Additional Paid-In Capital	896.7	896.7	900.77	1,109	116.16	116.16
Retained Earnings	515.62	484.08	502.91	508.18	416.3	296.24
Treasury Stock	-39	-39	-39	-	-	-
Comprehensive Income & Other	-0.41	-0.22	-0.19	0.41	0.21	0.03
Total Common Equity	1,798	1,767	1,790	1,854	709.96	589.72
Minority Interest	48.47	49.33	39.41	-0.16	-0.15	-0.09
Shareholders' Equity	1,847	1,816	1,829	1,854	709.81	589.63
Total Liabilities & Equity	2,397	2,311	2,229	2,040	941.52	833.49
Total Debt	321.48	242.65	176.27	23.16	108.9	126.42
Net Cash (Debt)	326.16	421.41	531.18	1,024	28.73	-32.92
Net Cash Growth	-29.74%	-20.67%	-48.14%	3465.41%	-	-
Net Cash Per Share	0.77	1.01	1.26	2.58	0.09	-0.11
Filing Date Shares Outstanding	423.51	423.51	423.51	425.5	425.5	319.12
Total Common Shares Outstanding	423.51	423.51	423.51	425.5	319.12	319.12
Working Capital	780.07	767.24	934.16	1,377	338.59	258.24
Book Value Per Share	4.25	4.17	4.23	4.36	2.22	1.85
Tangible Book Value	1,401	1,391	1,431	1,761	638.18	515
Tangible Book Value Per Share	3.31	3.28	3.38	4.14	2.00	1.61
Buildings	-	448.01	208.1	205.74	207.64	164.45
Machinery	-	284.45	203.9	187.35	171.81	151.26
Construction In Progress	-	2.44	247.02	66.37	2.01	-

Updated Oct 28, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.